{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:35:28Z","timestamp":1761489328822,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T00:00:00Z","timestamp":1394755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis A is a common viral liver disease and brings serious health and economic problems as its epidemiologic pattern changes over time. National serosurveys from developed countries have indicated a decline in HAV (hepatitis A virus) seroprevalence over time due to the improvement of economic and sanitation levels. The hepatitis A virus (HAV) immunity rate was surveyed throughout an eleven-year period by sex and age group in Aveiro District. In this retrospective study, blood samples from patients of Aveiro District, in ambulatory regime, collected at the Clinical Analysis Laboratory Avelab between 2002 and 2012 were screened for the presence of antibodies against HAV antigen using a chemiluminescence immunoassay. The global immunity (positive total anti-HAV) was 60% and only 0.3% of the patients presented recent infection by HAV (positive IgM anti-HAV). The HAV immunity was age-dependent (p &lt; 0.05), but no significant differences (p &gt; 0.05) between sexes were observed. The immunity was similar throughout the  study period (p &gt; 0.05). The results of this study indicate that young people (especially under 25 years old) from District of Aveiro are susceptible to HAV infection, constituting a high risk group. The elderly should be also a concern in the future of Hepatitis A infection.<\/jats:p>","DOI":"10.3390\/v6031336","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T13:18:11Z","timestamp":1394803091000},"page":"1336-1345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis A Immunity in the District of Aveiro (Portugal):  An Eleven-Year Surveillance Study (2002\u20132012)"],"prefix":"10.3390","volume":"6","author":[{"given":"Sara","family":"Pereira","sequence":"first","affiliation":[{"name":"Department of Biology and CESAM, University of Aveiro, Aveiro 3810-193, Portugal"}]},{"given":"In\u00eas","family":"Linhares","sequence":"additional","affiliation":[{"name":"Department of Biology and CESAM, University of Aveiro, Aveiro 3810-193, Portugal"}]},{"given":"Ant\u00f3nio","family":"Neves","sequence":"additional","affiliation":[{"name":"Clinical Analysis Laboratory Avelab, Rua Cer\u00e2mica do Vouga, Aveiro 3800-011, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8422-8664","authenticated-orcid":false,"given":"Adelaide","family":"Almeida","sequence":"additional","affiliation":[{"name":"Department of Biology and CESAM, University of Aveiro, Aveiro 3810-193, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2014,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/315701","article-title":"Duration of viremia in hepatitis A virus infection","volume":"182","author":"Bower","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.294.2.194","article-title":"Incidence of hepatitis A in the United States in the era of vaccination","volume":"294","author":"Wasley","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (1999). Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep., 48, 1\u201337."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1086\/314518","article-title":"The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies","volume":"178","author":"Bell","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/CMR.14.1.38-58.2001","article-title":"Hepatitis A: Old and new hepatitis A","volume":"14","author":"Cuthbert","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0264-410X(99)00470-3","article-title":"Clinical course and consequences of hepatitis A infection","volume":"18","author":"Ciocca","year":"2000","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/jhep.2003.50016","article-title":"Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults","volume":"37","author":"Rosenthal","year":"2003","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00019053-200927050-00003","article-title":"Costing infectious disease outbreaks for economic evaluation","volume":"27","author":"Luyten","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.vaccine.2009.10.136","article-title":"Hepatitis A and E: Update on prevention and epidemiology","volume":"28","author":"FitzSimons","year":"2010","journal-title":"Vaccine"},{"key":"ref_10","unstructured":"World Health Organization (2009). The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review, World Health Organization."},{"key":"ref_11","first-page":"103","article-title":"Hepatite A.: Altera\u00e7\u00e3o do padr\u00e3o epidemiol\u00f3gico?","volume":"16","author":"Marinho","year":"2000","journal-title":"Revist. Portug. Cl\u00edn. Geral"},{"key":"ref_12","first-page":"743","article-title":"Prevalence of viral hepatitis markers in the population of Portugal","volume":"62","author":"Lecour","year":"1984","journal-title":"Bull. World Health Org."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.vaccine.2013.02.048","article-title":"Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children","volume":"31","author":"Raczniak","year":"2013","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0264-410X(00)00188-2","article-title":"Inactivated hepatitis A vaccine booster given >\/=24 months after the primary dose","volume":"19","author":"Landry","year":"2000","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0264-410X(00)00166-3","article-title":"Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A\/B vaccine during the primary immunization course?","volume":"19","author":"Kallinowski","year":"2000","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1016\/j.vaccine.2007.10.001","article-title":"Cost-utility of universal hepatitis A vaccination in Canada","volume":"25","author":"Bauch","year":"2007","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archpedi.154.8.763","article-title":"The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates","volume":"154","author":"Jacobs","year":"2000","journal-title":"Arch. Paediatr. Adolesc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1440-1754.2003.00098.x","article-title":"Hepatitis A vaccination options for Australia","volume":"39","author":"MacIntyre","year":"2003","journal-title":"J. Paediatr. Child Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.vaccine.2005.01.065","article-title":"Efficiency of the incorporation of the hepatitis A vaccine as a combined A + B vaccine to the hepatitis B vaccination programme of preadolescents in schools","volume":"23","author":"Navas","year":"2005","journal-title":"Vaccine"},{"key":"ref_20","first-page":"10","article-title":"Recomenda\u00e7\u00f5es sobre vacinas","volume":"1","author":"Cavaco","year":"2010","journal-title":"Soc. Portug. Pediatr."},{"key":"ref_21","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade (2012). Norma da Dire\u00e7\u00e3o Geral da Sa\u00fade."},{"key":"ref_22","unstructured":"Rodrigues, L. (2004). Dire\u00e7\u00e3o Geral Sa\u00fade."},{"key":"ref_23","unstructured":"CDC (1999). Prevention of hepatitis A through active or passive immunization. Morbid. Mortal. Weekly Rep., 48, 1\u201337."},{"key":"ref_24","unstructured":"Operator\u2019s Guide. ADVIA Centaur\u00ae XP Immunoassay System. Available online:\t\t  http:\/\/healthcare.siemens.com\/immunoassay\/systems\/advia-centaur-xp\/."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/3\/1336\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:09:14Z","timestamp":1760216954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/3\/1336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,14]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3]]}},"alternative-id":["v6031336"],"URL":"https:\/\/doi.org\/10.3390\/v6031336","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2014,3,14]]}}}